Phil Ambery

598 total citations · 2 hit papers
9 papers, 357 citations indexed

About

Phil Ambery is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Phil Ambery has authored 9 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Molecular Biology and 2 papers in Surgery. Recurrent topics in Phil Ambery's work include Diabetes Treatment and Management (4 papers), Metabolism, Diabetes, and Cancer (3 papers) and Chronic Disease Management Strategies (2 papers). Phil Ambery is often cited by papers focused on Diabetes Treatment and Management (4 papers), Metabolism, Diabetes, and Cancer (3 papers) and Chronic Disease Management Strategies (2 papers). Phil Ambery collaborates with scholars based in United Kingdom, United States and Sweden. Phil Ambery's co-authors include Philip N. Newsome, Jill Donaldson, Jacqueline Parkin, Colin Dayan, N. Biswas, John P. Bilezikian, Alexander R. Cobitz, João Borges, Lorraine A. Fitzpatrick and Angela R. Jones-Leone and has published in prestigious journals such as The Lancet, Journal of Hepatology and Quality of Life Research.

In The Last Decade

Phil Ambery

8 papers receiving 348 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver

2023 104 citations Philip N. Newsome, Phil Ambery Journal of Hepatology profile →
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

2023 71 citations Hiddo J.L. Heerspink, Arihiro Kiyosue et al. The Lancet profile →

Peers

Phil Ambery

EDM

MB

SURGE

EPIDE

GENET

Rodis Paparodis United States

Kyeong Hye Park South Korea

Miyase Bayraktar Türkiye

María Teresa Julián Spain

Benjamin Ole Wolthers Denmark

K. Lucas United Kingdom

Scott T. Baker Australia

Daniele Cappellani Italy

Dalong Zhu China

Sophia Sakka Greece

Rodis Paparodis United States

Phil Ambery

241 ×1.2

EDM

64 ×0.6

MB

159 ×1.7

SURGE

36 ×0.4

EPIDE

33 ×0.5

GENET

Citations per year, relative to Phil Ambery Phil Ambery (= 1×) peers Rodis Paparodis

Countries citing papers authored by Phil Ambery

Since Specialization

Citations

This map shows the geographic impact of Phil Ambery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phil Ambery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phil Ambery more than expected).

Fields of papers citing papers by Phil Ambery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phil Ambery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phil Ambery. The network helps show where Phil Ambery may publish in the future.

Co-authorship network of co-authors of Phil Ambery

This figure shows the co-authorship network connecting the top 25 collaborators of Phil Ambery. A scholar is included among the top collaborators of Phil Ambery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phil Ambery. Phil Ambery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Heerspink, Hiddo J.L., Arihiro Kiyosue, David C. Wheeler, et al.. (2023). Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. The Lancet. 402(10416). 2004–2017. 71 indexed citations breakdown →

2.

Mandema, Jaap W., Hugh Montgomery, Louis Dron, et al.. (2023). Totality of evidence of the effectiveness of repurposed therapies for COVID‐19: Can we use real‐world studies alongside randomized controlled trials?. Clinical and Translational Science. 16(10). 1842–1855. 1 indexed citations

3.

Newsome, Philip N. & Phil Ambery. (2023). Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. Journal of Hepatology. 79(6). 1557–1565. 104 indexed citations breakdown →

4.

Ambery, Phil, et al.. (2013). Efficacy and safety of low‐dose otelixizumab anti‐CD3 monoclonal antibody in preserving C‐peptide secretion in adolescent type 1 diabetes: DEFEND‐2, a randomized, placebo‐controlled, double‐blind, multi‐centre study. Diabetic Medicine. 31(4). 399–402. 59 indexed citations

5.

Borges, João, John P. Bilezikian, Angela R. Jones-Leone, et al.. (2011). A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐na ï ve type 2 diabetes mellitus patients. Diabetes Obesity and Metabolism. 13(11). 1036–1046. 74 indexed citations

6.

Ambery, Phil, et al.. (2009). The new rosiglitazone story: Its place today in Type 2 diabetes management. Primary care diabetes. 3(1). 57–59. 1 indexed citations

7.

Schlotz, Wolff, Phil Ambery, Holly Syddall, et al.. (2006). Specific associations of insulin resistance with impaired health-related quality of life in the Hertfordshire Cohort Study. Quality of Life Research. 16(3). 429–436. 34 indexed citations

8.

Ambery, Phil & Ian Donald. (2000). Variation in general practice medical admission rates for elderly people. Journal of Public Health. 22(3). 422–426. 9 indexed citations

9.

Ambery, Phil, et al.. (2000). Does concurrent or previous illness accurately predict cardiac arrest survival?. Resuscitation. 47(3). 267–271. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact